Cite
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study
MLA
Ishida, Masaki, et al. “Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.” JTO Clinical and Research Reports, vol. 4, no. 4, Apr. 2023. EBSCOhost, https://doi.org/10.1016/j.jtocrr.2023.100493.
APA
Ishida, M., Morimoto, K., Yamada, T., Takeda, T., Shiotsu, S., Date, K., Harada, T., Tamiya, N., Chihara, Y., Takemura, Y., Yamada, T., Kanda, H., Iwasaku, M., Tokuda, S., Kim, Y. H., & Takayama, K. (2023). Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study. JTO Clinical and Research Reports, 4(4). https://doi.org/10.1016/j.jtocrr.2023.100493
Chicago
Ishida, Masaki, Kenji Morimoto, Tadaaki Yamada, Takayuki Takeda, Shinsuke Shiotsu, Koji Date, Taishi Harada, et al. 2023. “Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.” JTO Clinical and Research Reports 4 (4). doi:10.1016/j.jtocrr.2023.100493.